Mantle Cell Treatment Options
Dear OncoLink "Ask The Experts,"
I have Mantle cell lymphoma and have been given 2 options for treatment, hyper-CVAD or R-CHOP. From my readings, both are considered first-line approaches for treating MCL, however, hyper-CVAD is quite demanding on the patient. Why is hyper-CVAD preferred by some cancer centers over the less physically demanding R-CHOP? Does it have any advantages?
Babis (Charalambos) Andreadis, MD, Assistant Professor in Medicine in the Division of Hematology/Oncology at the Abramson Cancer Center and an Associate Scholar in the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania, responds:
Mantle cell lymphoma is an aggressive lymphoma that shares some of the issues with chemo-resistance seen in indolent lymphomas. Treatment considerations for this disease have traditionally revolved around 2 phases: remission induction and post-remission therapy. In terms of remission induction, CHOP and R-CHOP have been examined in the ‘90s and early ‘00s with discouraging results. It is not clear that any patient achieves a long-term remission with this regimen. As a matter of fact, there is a constant rate of relapse on this therapy, with the median duration of response and time to treatment failure being less than 2 years in the large randomized studies. In fact, most studies that have shown good long-term results with CHOP/R-CHOP have utilized it in conjunction with a stem cell transplant upon completion of therapy.
The hyper-CVAD+/- rituxan induction regimen was first developed in an attempt to overcome chemo-resistance in this disease. Data from MD Anderson suggest a significant response rate and duration of response utilizing it alone or followed by stem cell transplantation. As a matter of fact, 72% of patients treated with hCVAD/transplant were in remission 3 years after treatment, compared to 17% of patients treated with CHOP-like regimens at MD Anderson previously. In my opinion, hCAVD+/- rituxan is the induction regimen of choice for this disease. The question of a stem cell transplantation as post-remission therapy is still an open one and depends on individual factors and preferences.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania